---
title: "CMC regulatory consulting: IND to NDA and BLA | QLogixCMC"
description: "CMC consultants for biotech and pharma: CMC strategy, CTD Module 3 authoring, control strategy, specifications, stability, post-approval changes and tech transfer."
url: https://qlogixcmc.com/services/cmc-and-regulatory
markdown: https://qlogixcmc.com/services/cmc-and-regulatory.md
publisher: "QLogixCMC (QLogixCMC LLC)"
language: en-US
---

# CMC regulatory consulting: from IND to commercial supply
CMC consulting is the chemistry, manufacturing and controls work behind a regulatory submission: the control strategy, the specifications, the stability program, the manufacturing process description and the documents in Module 3 of the Common Technical Document. QLogixCMC plans that work for small molecules, biologics, sterile injectables, mRNA, cell immunotherapies and gene therapies, writes and reviews the documents from IND and IMPD through NDA, BLA and MAA, and supports the site through agency questions, post-approval changes and technology transfers.
[Request a meeting](https://qlogixcmc.com/contact)[All services](https://qlogixcmc.com/services)

## What we deliver
- CMC development strategy and the plan of studies for each phase
- Module 3 (CTD) authoring and review for IND, IMPD, NDA, BLA and MAA submissions
- Control strategy, critical quality attributes and critical process parameters
- Specifications, analytical method validation plans and stability protocols to ICH Q1A(R2)
- Process description, process validation strategy and comparability protocols
- Post-approval changes: classification, reporting category and supporting data
- Technology transfer packages and receiving-site readiness
- Preparation for pre-IND, end-of-phase and pre-approval meetings

## How the work runs
We begin with a CMC gap assessment of the development history, the data on hand and the target submission, and produce a plan that says which studies, documents and decisions are on the critical path. Writing starts from the data and the batch records, not from a template, so the narrative in Module 3 matches the evidence behind it.
Every document is reviewed against the ICH guideline it answers to and the agency's questions on similar products. For technology transfers, we run the gap analysis between sending and receiving sites, write the transfer protocol, and stay with the receiving site through the first batches.

## What makes it hold up under review
- Control strategy built on ICH Q8, Q9(R1), Q10 and Q11 principles, with the risk assessments on file
- Specifications justified to ICH Q6A and Q6B from the batch data and the clinical exposure
- Stability data presented to ICH Q1A(R2) and Q1E, with shelf-life proposals the data supports
- Post-approval changes classified under ICH Q12 and the applicable FDA and EMA guidance
- Every statement in the submission traceable to a report, a batch record or a validated method

## Your qualified people decide
- The sponsor's regulatory lead owns the submission strategy and signs off every document that goes to an agency.
- Specifications, shelf life and change classifications are proposed by us and decided by your qualified people.

## Frameworks this work is built to
- ICH M4Q (CTD)
- ICH Q1A(R2)
- ICH Q6A / Q6B
- ICH Q8 / Q11
- ICH Q9(R1)
- ICH Q12
- 21 CFR Parts 210/211
- EU GMP Part I

## Included
- CMC strategy
- Module 3 authoring
- Control strategy
- Specifications and stability
- Post-approval changes
- Technology transfer

## Questions about CMC and regulatory

### What does a CMC consultant do?

A CMC consultant plans and documents how a drug substance and a drug product are made, tested and controlled so that a regulatory submission can be approved and the product can be made consistently. At QLogixCMC that means the CMC development strategy, the control strategy, specifications and stability, the Module 3 sections of the CTD, agency meeting preparation, post-approval changes and technology transfers, drafted with the sponsor's team and decided by its qualified people.

### When should a biotech bring in CMC consulting?

Before the first IND or IMPD, when the CMC package is being built; before an end-of-phase meeting, when the control strategy and the validation plan are set; in the year before an NDA, BLA or MAA, when Module 3 is written and the pre-approval inspection is prepared; and whenever a technology transfer, a post-approval change or an agency question needs CMC expertise the team does not have. QLogixCMC starts each with a CMC gap assessment.

### Which products do you cover?

QLogixCMC works on small molecules, biologics, sterile injectables, mRNA and other nucleic acid products, cell immunotherapies such as CAR-T, gene therapies and drug-device combination products, for both drug substance and drug product. The team is assembled for the product: a biologics submission gets consultants who have run biologics processes, and an advanced therapy gets people who have released vector, cell and mRNA batches.

### Do you support mRNA, cell therapy and gene therapy CMC?

Yes. For mRNA, QLogixCMC covers the plasmid DNA template, in vitro transcription, lipid nanoparticle formulation, the identity, integrity, purity and potency specifications and the stability program. For cell immunotherapies, the apheresis starting material, the vector, the manufacturing process, release testing with a potency assay, chain of identity and custody, and the vein-to-vein timeline. For gene therapies, the plasmid and vector production, capsid and genome characterization, specifications and comparability through process changes. Submissions follow the FDA CBER and EMA ATMP guidance that applies.

### Can you write Module 3 from our data?

Yes. QLogixCMC authors Module 3 sections from your development reports, batch records, analytical data and stability tables, and reviews sections your team has written. Each statement is traced to the document that supports it, so the submission can be defended in an agency question.

### Do you support post-approval changes?

Yes. QLogixCMC classifies the change under ICH Q12 and the FDA or EMA guidance that applies, defines the supporting studies, writes the variation or supplement, and tracks the commitments to closure.

### How do you work with our regulatory affairs team?

As part of it. QLogixCMC drafts, reviews and advises; your regulatory lead owns the strategy and every document that goes to an agency. Where you have no regulatory function yet, we can act as the CMC regulatory lead until you hire one.

## Related services
- [Quality systems and QMSA pharmaceutical quality system designed for how your site actually runs: gap assessment, procedures, remediation, and the move from paper or a legacy QMS to a validated electronic one.](https://qlogixcmc.com/services/quality-systems)
- [Validation and computer software assuranceRisk-based validation of computerized systems, equipment and processes, following GAMP 5 (Second Edition) and FDA's computer software assurance guidance, documented for inspection.](https://qlogixcmc.com/services/validation-and-csa)
- [Investigations, CAPA and backlog remediationDeviation, OOS and complaint investigations that reach a defensible root cause, CAPAs that are checked for effectiveness, and aged backlogs cleared without lowering the standard.](https://qlogixcmc.com/services/investigations-and-capa)
- [Inspection readiness and compliance remediationFDA and EU GMP inspection readiness, mock inspections, internal and supplier audits, responses to FDA Form 483 observations and warning letters, and compliance remediation programs managed to closure.](https://qlogixcmc.com/services/inspection-readiness)
- [GxP systems implementation and administrationEngineers who implement the eQMS, LIMS, MES or document management system you have chosen, configure it to your SOPs, migrate and validate it, and then administer it for you day to day.](https://qlogixcmc.com/services/gxp-systems-implementation)
- [AI and digital qualityAI in the quality system done in a way an inspector can follow: use cases chosen by risk, governance and validation in place, and agentic workflows that draft while your people decide.](https://qlogixcmc.com/services/ai-and-digital-quality)

## Talk it through with someone who has run a plant
Bring your backlog, your submission timeline or the Form 483. We will tell you plainly what we would do first, what it would take, and what we would leave alone.
[Request a meeting](https://qlogixcmc.com/contact)[Email us](mailto:contact@qlogixcmc.com)

In the first meeting we cover
- What is on your mind: a backlog, a submission, a validation program, an inspection date or a system that is not working
- What we would assess first, and what we would leave alone
- Whether an engineer on your site, a fixed-scope assessment or a defined deliverable is the right way to start

## More from QLogixCMC

- [Quality systems and QMS](https://qlogixcmc.com/services/quality-systems.md): QMS gap assessments, SOP development, GMP remediation and the move from paper or a legacy QMS to a validated eQMS, for biotech, pharma, CDMOs and 503B facilities.
- [Validation and computer software assurance](https://qlogixcmc.com/services/validation-and-csa.md): Validation consulting for GMP sites: CSV and CSA for computerized systems, equipment qualification, process validation and AI-enabled systems, to GAMP 5 and FDA CSA.
- [Investigations, CAPA and backlog remediation](https://qlogixcmc.com/services/investigations-and-capa.md): Deviation, OOS and complaint investigations that reach a defensible root cause, CAPAs checked for effectiveness, and aged GMP backlogs cleared to the same standard.
- [Inspection readiness and compliance remediation](https://qlogixcmc.com/services/inspection-readiness.md): Mock FDA and EU GMP inspections, internal and supplier audits, Form 483 and warning letter responses, data integrity audits and compliance remediation to closure.
- [GxP systems implementation and administration](https://qlogixcmc.com/services/gxp-systems-implementation.md): Engineers who implement the eQMS, LIMS or MES you chose, configure it to your SOPs, migrate and validate it, and administer it for you, on site or remotely.
- [AI and digital quality](https://qlogixcmc.com/services/ai-and-digital-quality.md): AI governance, use-case selection, agentic workflow design, connected data and AI validation, so a GxP quality system adopts AI in a way an inspector can follow.
- [QLogixCMC home](https://qlogixcmc.com/index.md): CMC consulting for biotech, pharma and CDMOs: Module 3 from IND to BLA, control strategy, GMP quality systems, validation, CAPA and FDA inspection readiness.
- [Services](https://qlogixcmc.com/services.md): QLogixCMC services, on site or remote: CMC and regulatory, quality systems, validation and CSA, investigations and CAPA, inspection readiness, GxP systems and AI.
- [Request a meeting](https://qlogixcmc.com/contact.md): Talk to QLogixCMC about a CMC submission, your quality system, validation, an investigation backlog or an FDA inspection. We reply to set up a time.
- [llms.txt: a summary of the site for AI assistants](https://qlogixcmc.com/llms.txt)
- [Site map](https://qlogixcmc.com/sitemap.md)

---
Source: https://qlogixcmc.com/services/cmc-and-regulatory
Cite this page as https://qlogixcmc.com/services/cmc-and-regulatory
QLogixCMC · contact@qlogixcmc.com · +17146639012